|
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes |
Jun 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS |
Jun 2020 |
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
Jun 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey |
Jun 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
Jun 2020 |
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years |
Jun 2020 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Controversies on the Consequences of Iron Overload and Chelation in MDS |
May 2020 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
How I Diagnose Low-Grade Myelodysplastic Syndromes |
May 2020 |
American Journal of clinical Pathology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: Moving Towards Personalized Management |
May 2020 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
May 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
